Friday , 17 August 2018

Home » RESOURCES » MARKET » Samsung Bioepis seeks Europe approval for its Humira copy

Samsung Bioepis seeks Europe approval for its Humira copy

South Korean tech giant Samsung Group’s unit Samsung Bioepis, maker of biosimilars, said it is seeking Europe’s regulatory approval to sell its copy of AbbVie Inc’s rheumatoid arthritis drug Humira.

The company said the European Medicine Agency accepted its application for review of its drug Humira, which generated $14 billion in sales last year.

The material has been provided by InstaForex Company – www.instaforex.com

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Samsung Bioepis seeks Europe approval for its Humira copy Reviewed by on . South Korean tech giant Samsung Group's unit Samsung Bioepis, maker of biosimilars, said it is seeking Europe's regulatory approval to sell its copy of AbbVie I South Korean tech giant Samsung Group's unit Samsung Bioepis, maker of biosimilars, said it is seeking Europe's regulatory approval to sell its copy of AbbVie I Rating:
scroll to top